Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.
Identifieur interne : 001918 ( Main/Exploration ); précédent : 001917; suivant : 001919Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.
Auteurs : Jie Li [États-Unis] ; Laura Ulitzky ; Erica Silberstein ; Deborah R. Taylor ; Raphael ViscidiSource :
- Viral immunology [ 1557-8976 ] ; 2013.
Descripteurs français
- KwdFr :
- Analyse de survie, Animaux, Anticorps antiviraux (sang), Anticorps neutralisants (sang), Antigènes viraux (génétique), Antigènes viraux (immunologie), Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Modèles animaux de maladie humaine, Pliage des protéines, Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (immunologie), Protéines recombinantes (génétique), Protéines recombinantes (immunologie), Souris, Souris de lignée BALB C, Structure tertiaire des protéines, Syndrome respiratoire aigu sévère (), Test ELISA, Tests de neutralisation, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins sous-unitaires (administration et posologie), Vaccins sous-unitaires (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie), Virus du SRAS (génétique), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux, Vaccins sous-unitaires, Vaccins synthétiques.
- génétique : Antigènes viraux, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines recombinantes, Virus du SRAS.
- immunologie : Antigènes viraux, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines recombinantes, Vaccins antiviraux, Vaccins sous-unitaires, Vaccins synthétiques, Virus du SRAS.
- sang : Anticorps antiviraux, Anticorps neutralisants.
- Analyse de survie, Animaux, Glycoprotéine de spicule des coronavirus, Modèles animaux de maladie humaine, Pliage des protéines, Souris, Souris de lignée BALB C, Structure tertiaire des protéines, Syndrome respiratoire aigu sévère, Test ELISA, Tests de neutralisation.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Antigens, Viral (genetics), Antigens, Viral (immunology), Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Neutralization Tests, Protein Folding, Protein Structure, Tertiary, Recombinant Proteins (genetics), Recombinant Proteins (immunology), SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Survival Analysis, Vaccines, Subunit (administration & dosage), Vaccines, Subunit (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Vaccines, Subunit, Vaccines, Synthetic, Viral Vaccines.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , genetics : Antigens, Viral, Membrane Glycoproteins, Recombinant Proteins, Viral Envelope Proteins.
- chemical , immunology : Antigens, Viral, Membrane Glycoproteins, Recombinant Proteins, Vaccines, Subunit, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines.
- genetics : SARS Virus.
- immunology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Mice, Mice, Inbred BALB C, Neutralization Tests, Protein Folding, Protein Structure, Tertiary, Spike Glycoprotein, Coronavirus, Survival Analysis.
Abstract
Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.
DOI: 10.1089/vim.2012.0076
PubMed: 23573979
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001223
- to stream PubMed, to step Curation: 001223
- to stream PubMed, to step Checkpoint: 001159
- to stream Ncbi, to step Merge: 002649
- to stream Ncbi, to step Curation: 002649
- to stream Ncbi, to step Checkpoint: 002649
- to stream Main, to step Merge: 001925
- to stream Main, to step Curation: 001918
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.</title><author><name sortKey="Li, Jie" sort="Li, Jie" uniqKey="Li J" first="Jie" last="Li">Jie Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287</wicri:regionArea><wicri:noRegion>Maryland 21287</wicri:noRegion></affiliation></author><author><name sortKey="Ulitzky, Laura" sort="Ulitzky, Laura" uniqKey="Ulitzky L" first="Laura" last="Ulitzky">Laura Ulitzky</name></author><author><name sortKey="Silberstein, Erica" sort="Silberstein, Erica" uniqKey="Silberstein E" first="Erica" last="Silberstein">Erica Silberstein</name></author><author><name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R" last="Taylor">Deborah R. Taylor</name></author><author><name sortKey="Viscidi, Raphael" sort="Viscidi, Raphael" uniqKey="Viscidi R" first="Raphael" last="Viscidi">Raphael Viscidi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23573979</idno><idno type="pmid">23573979</idno><idno type="doi">10.1089/vim.2012.0076</idno><idno type="wicri:Area/PubMed/Corpus">001223</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001223</idno><idno type="wicri:Area/PubMed/Curation">001223</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001223</idno><idno type="wicri:Area/PubMed/Checkpoint">001159</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001159</idno><idno type="wicri:Area/Ncbi/Merge">002649</idno><idno type="wicri:Area/Ncbi/Curation">002649</idno><idno type="wicri:Area/Ncbi/Checkpoint">002649</idno><idno type="wicri:Area/Main/Merge">001925</idno><idno type="wicri:Area/Main/Curation">001918</idno><idno type="wicri:Area/Main/Exploration">001918</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.</title><author><name sortKey="Li, Jie" sort="Li, Jie" uniqKey="Li J" first="Jie" last="Li">Jie Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287</wicri:regionArea><wicri:noRegion>Maryland 21287</wicri:noRegion></affiliation></author><author><name sortKey="Ulitzky, Laura" sort="Ulitzky, Laura" uniqKey="Ulitzky L" first="Laura" last="Ulitzky">Laura Ulitzky</name></author><author><name sortKey="Silberstein, Erica" sort="Silberstein, Erica" uniqKey="Silberstein E" first="Erica" last="Silberstein">Erica Silberstein</name></author><author><name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R" last="Taylor">Deborah R. Taylor</name></author><author><name sortKey="Viscidi, Raphael" sort="Viscidi, Raphael" uniqKey="Viscidi R" first="Raphael" last="Viscidi">Raphael Viscidi</name></author></analytic><series><title level="j">Viral immunology</title><idno type="eISSN">1557-8976</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Antigens, Viral (genetics)</term><term>Antigens, Viral (immunology)</term><term>Disease Models, Animal</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Protein Folding</term><term>Protein Structure, Tertiary</term><term>Recombinant Proteins (genetics)</term><term>Recombinant Proteins (immunology)</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Survival Analysis</term><term>Vaccines, Subunit (administration & dosage)</term><term>Vaccines, Subunit (immunology)</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie</term><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Anticorps neutralisants (sang)</term><term>Antigènes viraux (génétique)</term><term>Antigènes viraux (immunologie)</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (génétique)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Modèles animaux de maladie humaine</term><term>Pliage des protéines</term><term>Protéines de l'enveloppe virale (génétique)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines recombinantes (génétique)</term><term>Protéines recombinantes (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Structure tertiaire des protéines</term><term>Syndrome respiratoire aigu sévère ()</term><term>Test ELISA</term><term>Tests de neutralisation</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins sous-unitaires (administration et posologie)</term><term>Vaccins sous-unitaires (immunologie)</term><term>Vaccins synthétiques (administration et posologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Subunit</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term><term>Membrane Glycoproteins</term><term>Recombinant Proteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term><term>Membrane Glycoproteins</term><term>Recombinant Proteins</term><term>Vaccines, Subunit</term><term>Vaccines, Synthetic</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins sous-unitaires</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes viraux</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines recombinantes</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines recombinantes</term><term>Vaccins antiviraux</term><term>Vaccins sous-unitaires</term><term>Vaccins synthétiques</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Protein Folding</term><term>Protein Structure, Tertiary</term><term>Spike Glycoprotein, Coronavirus</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term><term>Animaux</term><term>Glycoprotéine de spicule des coronavirus</term><term>Modèles animaux de maladie humaine</term><term>Pliage des protéines</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Structure tertiaire des protéines</term><term>Syndrome respiratoire aigu sévère</term><term>Test ELISA</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Silberstein, Erica" sort="Silberstein, Erica" uniqKey="Silberstein E" first="Erica" last="Silberstein">Erica Silberstein</name><name sortKey="Taylor, Deborah R" sort="Taylor, Deborah R" uniqKey="Taylor D" first="Deborah R" last="Taylor">Deborah R. Taylor</name><name sortKey="Ulitzky, Laura" sort="Ulitzky, Laura" uniqKey="Ulitzky L" first="Laura" last="Ulitzky">Laura Ulitzky</name><name sortKey="Viscidi, Raphael" sort="Viscidi, Raphael" uniqKey="Viscidi R" first="Raphael" last="Viscidi">Raphael Viscidi</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Li, Jie" sort="Li, Jie" uniqKey="Li J" first="Jie" last="Li">Jie Li</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001918 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001918 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23573979
|texte= Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23573979" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |